stockrow
Wednesday 11 November 2026
Export VIR’s income statement to Excel — free account
Vir Biotechnology, Inc.
VIRVir Biotechnology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $68.6 million, down 7.61% from fiscal 2024.
- Revenue
- −178.3%
- EPS
- +51.4%
- Free cash flow
- +36.8%
Quarter to September 2026, against a year earlier
13.12
0.03
−0.23%
Follow VIR
Alert me
Vir Biotechnology, Inc. (VIR) Operating margin
Vir Biotechnology, Inc.'s operating margin over the twelve months to 30 September 2026 was −69.8%, up 629.4 percentage points from fiscal 2025 (−699.2%). Over the past ten years it has ranged from −3,009.5% (fiscal 2017) to 51.6% (fiscal 2022); the current reading is higher than 67% of that period. That is below the Biotechnology industry median of 0.00% and below the Healthcare sector median of 0.00%.
Operating margin, annual
Embed this chart
Annual newest first
| Period | Operating margin | Change (points) |
|---|---|---|
| FY2025 | −699.2% | 92.09 |
| FY2024 | −791.3% | 2.77 |
| FY2023 | −794.0% | (845.60) |
| FY2022 | 51.6% | 13.15 |
| FY2021 | 38.4% | 427.29 |
| FY2020 | −388.9% | 1,810.84 |
| FY2019 | −2,199.7% | (1,087.12) |
| FY2018 | −1,112.6% | 1,896.89 |
| FY2017 | −3,009.5% | — |
Quarterly newest first
| Period | Operating margin | Change (points) |
|---|---|---|
| Sep 2026 | 55,669.2% | 55,638.40 |
| Jun 2026 | 30.8% | (456,141.66) |
| Mar 2026 | 456,172.4% | 456,247.20 |
| Dec 2025 | −74.8% | 72,193.13 |
| 28 more quarters | Free account |
Against its own ten years
Low −3,009.5%
High 51.6%
Ten-year median
−791.3%
Current reading's percentile
79
Operating margin against peers
| Company | Operating margin |
|---|---|
| ZYME Zymeworks Inc. compare | 16.6% |
| IMNM Immunome, Inc. compare | 0.00% |
| BHVN Biohaven Ltd. compare | 0.00% |
| REPL Replimune Group, Inc. compare | 0.00% |
| TRAX First Tracks Biotherapeutics, Inc. compare | 0.00% |
| VIR Vir Biotechnology, Inc. | −69.8% |
| LKFT Lakefront Biotherapeutics - Sponsored ADR compare | −90.1% |
| RXRX Recursion Pharmaceuticals, Inc. compare | −725.4% |
| NAMS NewAmsterdam Pharma Company N.V. compare | −900.1% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Operating margin is
EBIT Margin tells an investor how much operating profit, before interest and taxes, a company keeps from each unit of revenue.
EBIT ÷ Revenue
More on VIR
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement